期刊文献+

应用心衰超声指数评价慢性心力衰竭患者的临床价值 被引量:30

Value of heart failure echocardiography index for chronic heart failure evaluation
下载PDF
导出
摘要 目的:采用综合超声心动图多项参数的心衰超声指数评价慢性心力衰竭患者的心功能状态,旨在为临床提供更为全面、客观和量化的指标。方法:前瞻性研究慢性心力衰竭患者116例(心衰组),正常者24例(对照组),所有入选者进行心衰超声指数的评分,并将该评分与同期血浆氨基末端脑钠肽前体(NT-ProBNP)水平及纽约心功能分级(NYHA)进行比较,同时评价其诊断慢性心力衰竭的敏感性与特异性。结果:(1)心衰超声指数值在心衰组明显大于对照组,当心衰超声指数值大于≥3时,其诊断慢性有症状性心力衰竭的敏感性、特异性、阳性预测值、阴性预测值分别为88.6%、91.4%、96.8%及80.0%。(2)相关性分析表明心衰超声指数值与LogNT-ProBNP水平呈明显正相关(r=0.86,P<0.01)。(3)NYHAⅠ、Ⅱ、Ⅲ、Ⅳ级患者的心衰超声指数值分别为1.80±0.80、3.66±1.49、4.96±2.09和6.07±1.78,方差分析显示组间差异均有显著性(P<0.01)。结论:应用心衰超声指数来诊断慢性心衰及客观评价其严重程度是可行的,心衰超声指数作为综合评价慢性心衰患者心功能状态的一个新指标值得在临床推广应用。 Objective Heart failure echocardiography index (HFEI), which had synthesized multinomial parameters of echocardiography, was used to evaluate the cardiac function of patients with chronic heart failure (CHF) for the purpose of providing an objective, comprehensive, and quantitative criterion for appraising CHF. Methods HFEI in 116 patients with CHF (CHF group) and 24 normal controls (control group) were evaluated and compared with the levels of contemporaneous NT-ProBNP and the NYHA class, and the sensitivity and specificity of HFEI for CHF diagnosis were appraised. Results HFEI in CHF group was significantly higher than that in control group (P 〈 0.01). When the eutoff point of HFEI was set to be 3, the sensitivity, specificity, positive predictive value, and negative predictive value of HFEI for diagnosing CHF were 88.6%, 91.4%, 96.8%, and 80.0%. There was a remarkable positive correlation between HFEI and Log NT-ProBNP (r = 0.86, P 〈 0.01). There were significant differences of HFEI among NYHA class Ⅰ ,Ⅱ , Ⅲ ,and Ⅳ(1.80 ± 0.80, 3.66 ±1.49, 4.96 ± 2.09, 6.07 ± 1.78, P 〈 0.01). Conclusion HFEI can be used to diagnose CHF and evaluate the degree of it, and is worth generalizing.
出处 《实用医学杂志》 CAS 北大核心 2009年第12期1972-1974,共3页 The Journal of Practical Medicine
关键词 心力衰竭 充血性 心衰超声指数 氨基末端脑钠肽前体 Heart failure, congestive Heart failure echocardiography index NT-ProBNP
  • 相关文献

参考文献7

  • 1The European Society of Cardiology 2005. Guidelines for the diagnosis and treatment of chronic heart failure(update 2005) [J]. Eur Heart J, 2005, 26(11):1115-1140.
  • 2Cowie M R, Wood D A, Coats A J, et al. Survival of patients with a new diagnosis of heart failure: a population based study [J]. Heart, 2002, 83(5):505-510.
  • 3Cowie M R, Struthers D A, Coats A J, et al. Value of natriuretie peptides in assessment of patients with possible new heart failure in primary care [J]. Lancet, 1997, 350(9088): 1349-1353.
  • 4Pleton C P, Hatle L K. Relation of transmitral flow velocity patterns to left ventricular function: new insights from acombined hemodynamic and Doppler echocardiographic study [J]. J Am College of Cardiology, 1988,12(2):426-440.
  • 5Rossi A, Loredana L, Cicoira M, et al. Additional value of pulmonary vein parameters in defining pseudo normalization of mitral inflow pattern[J]. Echocardiograhy,2001,18(8):673-679.
  • 6Schirmer H, Lunde P, Rasmussen K. Mitral flow derived Doppler indices of left ventricular diastolic function in a general population [J]. Eur Heart J, 2002, 21(16):1376-1386.
  • 7张慧平,孙福成.B型利钠肽与心力衰竭[J].中华老年医学杂志,2005,24(10):790-793. 被引量:17

二级参考文献32

  • 1Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation, 1997, 96:509-516.
  • 2Adams KF , Mathur VS, Gheorghiade M. B-type natriuretic peptide: from bench to bedside. Am Heart J, 2003, 145:S34-46.
  • 3Chen HH, Burnett JC. The natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep, 2000, 3:198-205.
  • 4Christian H. Essential biochemistry and physiology of (NT-pro)BNP. EurJ Heart Fail, 2004, 6:257-260.
  • 5Wu A, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. EurJ Heart Fail, 2004, 6:355-358.
  • 6Hystad ME, Geiran OR, Attramadal H, et al.Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand, 2001, 171 :395-403.
  • 7Magga J, Marttila M, Mantymaa P, et al. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats.Endocrinology, 1994, 134:2505-2515.
  • 8Harada M, Saito Y, Kuwahara K, et al. Interaction of myocytes and non-myocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J Cardiovasc Pharmacol, 1998, 31(suppl 1):S357-359.
  • 9Thuerauf DJ, Glembotski CC. Differential effects of protein kinase C, ras, and raf-1 kinase on the induction of the cardiac B-type natriuretic peptide gene through a critical promoter-proximal MCAT element. J Biol Chem, 1997, 272:7464-7472.
  • 10Ambrose TM. A review of the clinical utility of NT-pro BNP in the diagnosis, prognosis, and therapy monitoring of patients with congestive heart failure. J Clin Ligand Assay, 2003, 25:160-166.

共引文献16

同被引文献163

引证文献30

二级引证文献195

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部